Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 1997 Jul 7;186(1):147–152. doi: 10.1084/jem.186.1.147

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Angiogenesis in wild-type mice and in mice lpr Fas-mutant stimulated with agonistic (mAb Jo2) and nonagonistic (mAb RMF6) anti-Fas mAbs and role of heparin in Fas-induced angiogenesis. 5 μg/ml anti-Fas mAb Jo2 or RMF6 were used. As standard procedure Matrigel was supplemented with 64 U/ml heparin (see Materials and Methods). In selected experiments, heparin was omitted or 64 μg/ml protamine was added. b-FGF was used at the dose of 10 ng/ml. The results were expressed as percentage ± SE of the vessel area to the total Matrigel area. ANOVA with Newmann-Keuls multi-comparison test was performed: control vs. mAb Jo2, mAb RMF6, and b-FGF (*P <0.05); mAb Jo2 in wild-type mice vs. mAb RMF6, mAb Jo2 without heparin, mAb Jo2 plus protamine, mAb Jo2 in lpr mice (^§ P <0.05).